Life Science News

RSS

Malvern image analysis system measures sub-visible particulates in biotherapeutics

Specialists at Malvern Panalytical have demonstrated the application of dynamic particle image analysis to the measurement of sub-visible particulates in biological therapeutics, using the Sysmex FPIA-3000 particle characterization system.

From Malvern Panalytical 18 Mar 2010

Avid Bioservices highlights data of single-use bioreactors and traditional stainless steel bioreactors

Avid Bioservices, Inc. today presented data highlighting the comparability of production run performance between the company's single-use bioreactors (Thermo Scientific HyClone S.U.B.) and its traditional stainless steel bioreactors at the Thermo Scientific BioProduction Optimization Workshop in San Francisco, California.

From Thermo Fisher Scientific Inc. 17 Mar 2010

Illumina announces enhancement to OmniExpress BeadChip

Illumina, Inc. today unveiled its new HumanOmniExpress+ Custom BeadChip (OmniExpress+), an enhancement to the recently announced OmniExpress BeadChip that allows for the addition of up to 200,000 custom variants for a total of >900k variants per sample. OmniExpress+ leverages the proven iSelect custom genotyping infrastructure to provide researchers with unlimited flexibility in adding custom content for disease or pathway-specific markers, rare variants from the 1,000 Genomes Project, or panels for fine-mapping onto the industry’s most optimal set of SNPs.

From Illumina, Inc. 16 Mar 2010

Roche Diagnostics named sole source supplier for Premier's blood glucose monitoring devices

Roche Diagnostics announced today that it has been awarded contracts for blood glucose monitoring and clinical chemistry/immunoassay lab analyzers from Premier Purchasing Partners, L.P., Inc., the group purchasing unit of Premier, Inc. Roche was also named the sole source supplier for blood glucose in Premier's exclusive ASCEND supply chain performance program.

From Roche Sequencing and Life Science 16 Mar 2010

Cytori Therapeutics reports total revenues of $14.7M for 2009

Cytori Therapeutics is reporting its financial results for the year ended December 31, 2009.

From Evident Corporation - Life Sciences 12 Mar 2010

Peregrine Pharmaceuticals' third-quarter fiscal 2010 total revenues up 45%

Peregrine Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and serious viral infections, today announced financial results for the third quarter of fiscal year (FY) 2010 ended January 31, 2010. The company also provided an update on its clinical programs and corporate developments.

From Thermo Fisher Scientific Inc. 11 Mar 2010

Illumina sequences DNA of American actress Glenn Close

Illumina, Inc. today announced that it has sequenced the DNA of American actress Glenn Close, the first publicly named female to have her DNA sequenced to full coverage.

From Illumina, Inc. 11 Mar 2010

Sartorius achieves operating earnings of 60.9M euros for 2009

Sartorius, a leading international laboratory and process equipment provider, increased its operating profit in 2009 despite the difficult macroeconomic climate and achieved operating earnings of 60.9 million euros, up from 56.8 million euros a year earlier. “As a result, we are among the companies that were able to close the 2009 year of crisis with a positive development of operating earnings,” commented CEO Dr. Joachim Kreuzburg on the company’s full-year results at the annual press conference in Goettingen, Germany.

From Sartorius 9 Mar 2010

Thermo Fisher Scientific acquires Finnzymes

Thermo Fisher Scientific Inc., the world leader in serving science, has completed its previously announced acquisition of Finnzymes. The business is a well-recognized provider of integrated tools for high-performance polymerase chain reaction (PCR), including reagents, instruments, consumables and kits that make the PCR process faster and more accurate for applications including basic genomic research, genetic testing, forensics and food safety.

From Thermo Fisher Scientific Inc. 5 Mar 2010

Olympus America signs nonexclusive worldwide licensing agreement with Omnyx

Olympus America Inc. has signed a nonexclusive worldwide licensing agreement with Omnyx, LLC, a joint venture of GE Healthcare and the University of Pittsburgh Medical Center, allowing Omnyx to access an extensive portfolio of Olympus America patents in the field of virtual microscopy and digital pathology, to help develop solutions in the digital pathology field.

From Evident Corporation - Life Sciences 1 Mar 2010

CAMH signs licensing agreement with US-based Athena Diagnostics to market new genetic test

For the second time in as many months the Centre for Addiction and Mental Health has signed a licensing agreement with US-based Athena Diagnostics Inc. to market a new genetic test.

From Thermo Fisher Scientific Inc. 26 Feb 2010

Thermo Fisher Scientific completes previously announced acquisition of Ahura Scientific

Thermo Fisher Scientific Inc., the world leader in serving science, today announced that it has completed its previously announced acquisition of Ahura Scientific, a leader in handheld Raman and FT-IR (Fourier-transform infrared) spectroscopy instruments that are used worldwide in the identification of chemicals for safety, security and pharmaceutical applications.

From Thermo Fisher Scientific Inc. 26 Feb 2010

Pall Corporation announces next generation, 96-well AcroPrep Advance filter plates

Pall Corporation, a global leader in filtration, separation and purification, has introduced its next generation 96-well filter plate that delivers consistency and reproducibility in applications, such as neonatal screening and multiplexing. The Pall AcroPrep Advance filter plate employs new design features that provide uniform filtration rates, lowers hold-up volumes and ensures consistent sample/bead recovery from the wells.

From Pall Corporation 26 Feb 2010

Unique technology identifies drug candidates, speeds up drug development

The search for new therapeutic agents is time-consuming and expensive. Pharmaceutical companies may have to screen thousands of compounds for the ability to bind a target molecule before they hit upon a promising drug candidate.

From NanoTemper Technologies 24 Feb 2010

New England Biolabs adds NEBNext DNA Sample Prep Master Mix Set 3 for use with Life Technologies' SOLiD 3 System

New England Biolabs has expanded its line of reagents for sample preparation to include NEBNext™ DNA Sample Prep Master Mix Set 3, which has been validated for use with the SOLiD™ 3 System from Life Technologies. NEBNext reagents are a series of highly pure reagents that facilitate sample preparation for downstream applications, such as next generation sequencing. All reagents undergo stringent quality controls and functional validation, ensuring maximum yield, convenience and value.

From New England Biolabs 24 Feb 2010

Olympus launches new medical devices for LESS surgery

A variety of new medical devices specifically designed for Laparo-Endoscopic Single-Site surgery (LESS surgery) has been announced and introduced by Olympus Europa Holding GmbH and Olympus Medical Systems Corporation. LESS surgery is an advanced, minimally invasive operation technique by which an endoscope and hand instruments are inserted through an access port anchored in just one small incision, usually made in the navel. After developing all the medical devices needed to perform LESS surgery, Olympus has yet again proven its leadership in the field. The release of these innovative devices in Europe took place in autumn 2009.

From Evident Corporation - Life Sciences 18 Feb 2010

QIAGEN N.V. enters into agreement to distribute Celera molecular multiplex assay

QIAGEN N.V. and Celera Corporation today announced an agreement under which QIAGEN will distribute a Celera molecular multiplex assay. The assay is the next generation version of QIAGEN’s ResPlex II assay for detection of respiratory pathogens.

From QIAGEN Manchester Limited 11 Feb 2010

Sartorius releases preliminary unaudited figures for fiscal 2009

Today Sartorius, a leading international process and laboratory technology provider, released its preliminary unaudited figures for fiscal 2009. In the reporting period, business in both Group divisions showed substantially divergent trajectories.

From Sartorius 10 Feb 2010

New filtration process to improve safety and quality of infant formula

Pall Corporation, a global leader in filtration, separation and purification, today introduced a new filtration process that significantly improves the safety and quality of infant formula. The Pall process is engineered to prevent microbial contamination through intensive filtration, while preserving nutritional quality by minimizing the need for repeated heat treatment during manufacturing.

From Pall Corporation 10 Feb 2010

Morphologi G3 adds new dimension to Solvay Pharmaceuticals R&D

Solvay Pharmaceuticals Inc. (Marietta, GA, USA) was the first company in the United States to install the innovative Morphologi G3 image analysis-based particle characterization system from Malvern Panalytical.

From Malvern Panalytical 9 Feb 2010